作者
Guoli Wang,Hu Deng,Ge Wang,Nini Qu
摘要
Pulmonary metastasis is a major cause of mortality in patients with colorectal cancer (CRC), but the underlying mechanisms remain incompletely understood. The gut-lung axis, which links the gut microbiota to lung homeostasis, has emerged as a key regulator of CRC progression and metastasis. Traditional Chinese medicine (TCM), based on the classical theory of the “interior-exterior relationship between the lung and large intestine”, may exert therapeutic effects through modulation of this axis. This review aimed to summarize the mechanisms by which the gut-lung axis regulates CRC pulmonary metastasis and to evaluate TCM-based interventions targeting this axis. A systematic search was conducted in PubMed, Web of Science, and China National Knowledge Infrastructure up to March 2026. Clinical and preclinical studies were included. Gut microbiota dysbiosis, characterized by enrichment of Faecalibacterium and enterotoxigenic Bacteroides fragilis , promotes epithelial-mesenchymal transition (EMT), remodels the pre-metastatic niche (PMN), and contributes to chemoresistance. Exosomes carrying specific microRNAs and circular RNAs can reach the lungs and create a microenvironment favorable for metastasis. Gut-derived immune cells, particularly T helper 17 and regulatory T cells, migrate to the lungs and shape local immune responses. In addition, the gut-lung leak axis driven by lipopolysaccharide/Toll-like receptor 4 signaling exacerbates pulmonary inflammation. TCM formulas, including Si-Jun-Zi decoction and combinations of Sophora japonica and Scutellaria baicalensis , as well as active compounds such as geniposide, berberine, and Astragalus polysaccharides, may restore microbial diversity, repair intestinal barrier function, inhibit EMT, and regulate exosome release. However, clinical evidence remains limited, and substantial translational challenges persist. The gut-lung axis represents a promising therapeutic target for CRC lung metastasis. Although TCM may regulate this axis through multiple mechanisms, current evidence is predominantly preclinical. Further mechanistic studies, particularly those clarifying causal relationships among microbial taxa, exosomal cargoes, and lung PMN formation, are needed before reliable clinical translation can be achieved. Well-designed randomized controlled trials remain essential for validating TCM-based interventions.